Huang, Shan
Thomsson, Kristina A.
Jin, Chunsheng
Alweddi, Sally
Struglics, André
Rolfson, Ola
Björkman, Lena I.
Kalamajski, Sebastian
Schmidt, Tannin A.
Jay, Gregory D.
Krawetz, Roman
Karlsson, Niclas G.
Eisler, Thomas
Funding for this research was provided by:
Vetenskapsrådet (621-2013-5895, 621-2013-5895, 621-2013-5895, 621-2013-5895, 621-2013-5895)
ALF (ALFGBG-722391, ALFGBG-722391, ALFGBG-722391, ALFGBG-722391, ALFGBG-722391)
Kung Gustav V:s 80-års foundation
Petrus and Augusta Hedlund’s foundation (M-2016-0353, M-2016-0353, M-2016-0353, M-2016-0353, M-2016-0353)
IngaBritt och Arne Lundbergs Forskningsstiftelse, Sweden
AFA insurance research fund (dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150, dnr 150150)
Article History
Received: 21 August 2019
Accepted: 20 February 2020
First Online: 6 March 2020
Change Date: 15 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-020-77619-5
Competing interests
: G.D.J., R.K. and T.A.S. authored patents related to rhPRG4 and hold equity in Lubris BioPharma, LLC. TAS is also a paid consultant for Lubris BioPharma, LLC. S.K., C.J. and N.G.K. authored a patent using lubricin for diagnostics. S.H., K.A.T., S.A. A.S., O.R., L.I.B., R.K. and T.E. declare no competing interest.